Researchers are cautiously optimistic about pozelimab, a novel antibody showing encouraging results in initial clinical assessments. This therapeutic targets aggregated tau – a significant hallmark of https://bookmark-template.com/story29391990/pozelimab-a-new-breakthrough-for-the-disease